1
|
Tsai YS, Tsai WC, Chiu LT, Kung PT. Diabetes Pay-for-Performance Program Participation and Dialysis Risk in Relation to Educational Attainment: A Retrospective Cohort Study. Healthcare (Basel) 2023; 11:2913. [PMID: 37998405 PMCID: PMC10671833 DOI: 10.3390/healthcare11222913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2023] [Revised: 11/03/2023] [Accepted: 11/05/2023] [Indexed: 11/25/2023] Open
Abstract
Pay-for-performance (P4P) programs for diabetes care enable the provision of comprehensive and continuous health care to diabetic patients. However, patient outcomes may be affected by the patient's educational attainment. The present retrospective cohort study aimed to examine the effects of the educational attainment of diabetic patients on participation in a P4P program in Taiwan and the risk of dialysis. The data were obtained from the National Health Insurance Research Database of Taiwan. Patients newly diagnosed with type 2 diabetes mellitus (T2DM) aged 45 years from 2002 to 2015 were enrolled and observed until the end of 2017. The effects of their educational attainment on their participation in a P4P program were examined using the Cox proportional hazards model, while the impact on their risk for dialysis was investigated using the Cox proportional hazards model. The probability of participation in the P4P program was significantly higher in subjects with a junior high school education or above than in those who were illiterate or had only attained an elementary school education. Subjects with higher educational attainment exhibited a lower risk for dialysis. Different educational levels had similar effects on reducing dialysis risk among diabetic participants in the P4P program.
Collapse
Affiliation(s)
- Yi-Shiun Tsai
- Department of Orthopedics, Feng Yuan Hospital, Taichung 420210, Taiwan;
- Department of Health Services Administration, College of Public Health, China Medical University, Taichung 406040, Taiwan; (W.-C.T.); (L.-T.C.)
| | - Wen-Chen Tsai
- Department of Health Services Administration, College of Public Health, China Medical University, Taichung 406040, Taiwan; (W.-C.T.); (L.-T.C.)
| | - Li-Ting Chiu
- Department of Health Services Administration, College of Public Health, China Medical University, Taichung 406040, Taiwan; (W.-C.T.); (L.-T.C.)
| | - Pei-Tseng Kung
- Department of Healthcare Administration, Asia University, Taichung 413305, Taiwan
- Department of Medical Research, China Medical University Hospital, Taichung 404327, Taiwan
| |
Collapse
|
2
|
Kaur S, Garg A, Kaushal N. Hempseed (Cannabis sativa) offers effective alternative over statins in ameliorating hypercholesterolemia associated nephropathy. Clin Biochem 2021; 93:104-111. [PMID: 33861983 DOI: 10.1016/j.clinbiochem.2021.04.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 03/24/2021] [Accepted: 04/09/2021] [Indexed: 01/05/2023]
Abstract
A direct link between hypercholesterolemia (HC) and renal pathologies has been established. Statins, the drugs of choice for HC management, have been associated with various side effects and toxicities, including nephropathy and other renal insults. Thus, natural dietary products based-alternative strategies for HC and associated pathologies are being considered. OBJECTIVES Based on the unique nutritional composition and numerous health benefits of Hempseeds (Cannabis sativa), currently the potential anti-inflammatory and redox modulatory effects of hempseeds lipid extract (HEMP) against HC associated renal damage were evaluated and compared with statins (Simvastatin) in HFD induced experimental model of HC in rats. DESIGN & METHODS The hempseed lipid fractions (HEMP) were prepared and their ameliorating effects on HFD induced lipid profiles, renal function markers (RFT), histopathological/morphological changes, renal oxidative stress, and inflammation markers were studied and compared with statins (HFD + STATINS). Further, HEMP-mediated modulation of lipid metabolism mediators (APO-B/E) was studied. RESULTS Not only, HEMP administration improved the lipid profiles and morphological signs of HC, but it also was safe compared to Simvastatin in terms of hepatic and renal function markers. Further, changes in renal histoarchitecture, biochemical markers of oxidative stress, and expression profiles of lipid metabolism and inflammatory pathways (Cox-1/2, PGDS, PGES) revealed that HEMP positively modulating the redox homeostasis activated the resolution pathways against HC associated renal insults. CONCLUSION The outcomes of the current study indicated HEMP's ameliorative and therapeutic potential against hypercholesterolemia-associated nephropathies and other systemic effects.
Collapse
Affiliation(s)
- Simarpreet Kaur
- Department of Biophysics, Panjab University, Chandigarh 160014, India
| | - Ayushi Garg
- Department of Biophysics, Panjab University, Chandigarh 160014, India
| | - Naveen Kaushal
- Department of Biophysics, Panjab University, Chandigarh 160014, India.
| |
Collapse
|
3
|
G B, V G, T S, A S MK, C HK, G SK. Hypolipidemic and Antioxidant Properties of Oryzanol Concentrate in Reducing Diabetic Nephropathy via SREBP1 Downregulation Rather than β-Oxidation. Mol Nutr Food Res 2018; 62:e1700511. [PMID: 29469229 DOI: 10.1002/mnfr.201700511] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Revised: 01/31/2018] [Indexed: 10/18/2022]
Abstract
SCOPE Diabetic nephropathy (DN) is a micro-vascular complication of chronic diabetes. Sterol regulatory element binding protein1 (SREBP1) participation in the development of DN is reported. Oryzanol concentrate (OC) at 0.1% and 0.3% is tested for its antioxidant and hypolipidemic effects. The aim of the work is to study the involvement of OC in the amelioration of DN in STZ-induced diabetic animal model. METHODS AND RESULTS Animals were grouped into starch, high-fat, and OC-treated control/diabetic groups (SFC/SFD, HFC/HFD, OFC/OFD). The markers of DN, increased glomerular filtration rate and kidney weight, were evident in HFD and reduced in OFD group by ≈1.09 and ≈1.3 fold, respectively. The amelioration of defensive antioxidant enzyme activities and lipid peroxidation, expressions of lipid-associated biomolecules (SREBP1 and FAS) were also observed. HFD showed increased ECM accumulation of glycoproteins, particularly Type IV collagen, fibronectin. SREBP1-associated gene transforming growth factor-β (TGF-β) was reduced on treatment (OFD ≈ 1.3 fold) as to HFD (≈2.7 fold). CONCLUSION Oryzanol concentrate, having hypolipidemic and antioxidant properties, also downregulated the lipid biosynthesis through reduced SREBP1-TGF-β interactions (EMSA) and could effectively ameliorate DN. Gene (ACC2, Cpt1, and ACOX) expression studies showed that β-oxidation was not involved in reducing DN.
Collapse
Affiliation(s)
- Bhaskaragoud G
- Department of Biochemistry, CSIR-Central Food Technological Research Institute, Mysore, India
| | - Geetha V
- Department of Biochemistry, CSIR-Central Food Technological Research Institute, Mysore, India
| | - Sharanappa T
- Department of Biochemistry, CSIR-Central Food Technological Research Institute, Mysore, India
| | - Mohan Kumar A S
- Department of Biochemistry, CSIR-Central Food Technological Research Institute, Mysore, India
| | - Hema Kumar C
- Department of Biochemistry, CSIR-Central Food Technological Research Institute, Mysore, India
| | - Suresh Kumar G
- Department of Biochemistry, CSIR-Central Food Technological Research Institute, Mysore, India
| |
Collapse
|
4
|
Adejor EB, Ameh DA, James DB, Owolabi OA, Ndidi US. Effects of Garcinia kola biflavonoid fractions on serum lipid profile and kidney function parameters in hyperlipidemic rats. CLINICAL PHYTOSCIENCE 2016. [DOI: 10.1186/s40816-016-0033-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
5
|
Abstract
PURPOSE OF REVIEW Foam cells in human glomeruli can be encountered in various renal diseases including focal segmental glomerulosclerosis and diabetic nephropathy. Although foam cells are key participants in atherosclerosis, surprisingly little is known about their pathogenicity in the kidney. We review our understanding (or lack thereof) of foam cells in the kidney, as well as insights gained in studies of foam cells and macrophages involved in atherosclerosis to suggest areas of investigation that will allow better characterization of the role of these cells in renal disease. RECENT FINDINGS There is a general dearth of animal models of disease with renal foam cell accumulation, limiting progress in our understanding of the pathobiology of these cells. Recent genetic modifications of hyperlipidemic mice have resulted in some new disease models with renal foam cell accumulation. Recent studies have challenged older paradigms by findings that indicate that many tissue macrophages are derived from cells permanently residing in the tissue from birth rather than circulating monocytes. SUMMARY Renal foam cells remain an enigma. Extrapolating from studies of atherosclerosis suggests that therapeutics targeting mitochondrial reactive oxygen species production, or modulating cholesterol and lipoprotein uptake or egress from these cells, may prove beneficial for kidney diseases in which foam cells are present.
Collapse
|
6
|
Urinary exosomes: a novel means to non-invasively assess changes in renal gene and protein expression. PLoS One 2014; 9:e109631. [PMID: 25310591 PMCID: PMC4195685 DOI: 10.1371/journal.pone.0109631] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Accepted: 09/07/2014] [Indexed: 12/17/2022] Open
Abstract
Background In clinical practice, there is a lack of markers for the non-invasive diagnosis and follow-up of kidney disease. Exosomes are membrane vesicles, which are secreted from their cells of origin into surrounding body fluids and contain proteins and mRNA which are protected from digestive enzymes by a cell membrane. Methods Toxic podocyte damage was induced by puromycin aminonucleoside in rats (PAN). Urinary exosomes were isolated by ultracentrifugation at different time points during the disease. Exosomal mRNA was isolated, amplified, and the mRNA species were globally assessed by gene array analysis. Tissue-specific gene and protein expression was assessed by RT-qPCR analysis and immunohistochemistry. Results Gene array analysis of mRNA isolated from urinary exosomes revealed cystatin C mRNA as one of the most highly regulated genes. Its gene expression increased 7.5-fold by day 5 and remained high with a 1.9-fold increase until day 10. This was paralleled by a 2-fold increase in cystatin C mRNA expression in the renal cortex. Protein expression in the kidneys also dramatically increased with de novo expression of cystatin C in glomerular podocytes in parts of the proximal tubule and the renal medulla. Urinary excretion of cystatin C increased approximately 2-fold. Conclusion In this proof-of-concept study, we could demonstrate that changes in urinary exosomal cystatin C mRNA expression are representative of changes in renal mRNA and protein expression. Because cells lining the urinary tract produce urinary exosomal cystatin C mRNA, it might be a more specific marker of renal damage than glomerular-filtered free cystatin C.
Collapse
|
7
|
Awad NE, Hamed MA, Seida AA, Elbatanony MM. Efficacy of Ficus spp. on renal injury induced by hypercholesterolaemia. Nat Prod Res 2012; 26:1561-4. [PMID: 22432976 DOI: 10.1080/14786419.2011.570760] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The ethanol and hexane extracts of Ficus microcarpa, Ficus religiosa and Ficus mysorensis leaves were evaluated against renal injury induced by hypercholesterolaemia. Phytochemical screening of the investigated plants was undertaken. For the in vivo study, all rats were orally given cholesterol (30 mg kg⁻¹ body weight, BW) and leaves extract (500 mg kg⁻¹ BW) five times per week for 9 weeks. Hypercholesterolaemic rats showed significant increases in urea nitrogen and creatinine while serum protein and albumin levels, nitric oxide (NO), Na⁺-K⁺-ATPase and phospholipids in kidney tissue were all decreased. Treatment with leaves extract improved kidney function indices (urea nitrogen, creatinine, serum protein and albumin), kidney disorder biochemical parameters (NO, Na⁺-K⁺-ATPase and phospholipids), haematological profile (haemoglobin, RBCs and WBCs) and kidney histopathology. In conclusion, Ficus spp. succeeded in improving renal injury induced by hypercholesterolaemia, with the most potent effects seen while using Ficus microcarpa hexane extract.
Collapse
Affiliation(s)
- Nagwa E Awad
- Department of Pharmacognosy, National Research Centre, Cairo, Egypt
| | | | | | | |
Collapse
|
8
|
van Roeyen CRC, Ostendorf T, Floege J. The platelet-derived growth factor system in renal disease: an emerging role of endogenous inhibitors. Eur J Cell Biol 2011; 91:542-51. [PMID: 21872965 DOI: 10.1016/j.ejcb.2011.07.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2011] [Revised: 07/05/2011] [Accepted: 07/05/2011] [Indexed: 01/28/2023] Open
Abstract
The platelet-derived growth factor (PDGF) family consists of four isoforms which are secreted as homodimers (PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD) or heterodimers (PDGF-AB), and two receptor chains (PDGFR-α and -β). All members of the PDGF system are constitutively or inducibly expressed in renal cells and are involved in the regulation of cell proliferation and migration, the accumulation of extracellular matrix proteins and the secretion of pro- and anti-inflammatory mediators. Particular roles have been identified in mediating mesangioproliferative changes, renal interstitial fibrosis and glomerular angiogenesis. Different endogenous inhibitors of PDGF-induced biological responses exist which affect the activation/deactivation of PDGF isoforms, the activity of the PDGFRs, or which block downstream signaling pathways of the autophosphorylated PDGFRs. The novel endogenous inhibitor nephroblastoma overexpressed gene (NOV, CCN3) reduces PDGF-induced cell proliferation and is downregulated by PDGF isoforms itself. Among all identified inhibitors only few "true" PDGF antagonists have been identified. A better understanding of these inhibitors may aid in the design of novel therapeutic approaches to PDGF-mediated diseases.
Collapse
Affiliation(s)
- Claudia R C van Roeyen
- Department of Nephrology and Clinical Immunology, RWTH University Hospital Aachen, Pauwelsstr. 30, D-52057 Aachen, Germany.
| | | | | |
Collapse
|
9
|
Thompson J, Wilson P, Brandewie K, Taneja D, Schaefer L, Mitchell B, Tannock LR. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. THE AMERICAN JOURNAL OF PATHOLOGY 2011; 179:1179-87. [PMID: 21723246 DOI: 10.1016/j.ajpath.2011.05.016] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2010] [Revised: 04/27/2011] [Accepted: 05/05/2011] [Indexed: 11/19/2022]
Abstract
Hyperlipidemia worsens diabetic nephropathy, although the mechanism by which renal lipids accumulate is unknown. We previously demonstrated that renal proteoglycans have high low-density lipoprotein (LDL) binding affinity, suggesting that proteoglycan-mediated LDL retention may contribute to renal lipid accumulation. The aim of this study was to determine the relative effect of diabetes and hyperlipidemia on renal proteoglycan content. Diabetic and non-diabetic LDL receptor-deficient mice were fed diets containing 0% or 0.12% cholesterol for 26 weeks, and then kidneys were analyzed for renal lipid and proteoglycan content. Diabetic mice on the high-cholesterol diet had accelerated development of diabetic nephropathy with elevations in urine albumin excretion, glomerular and renal hypertrophy, and mesangial matrix expansion. Renal lipid accumulation was significantly increased by consumption of the 0.12% cholesterol diet, diabetes, and especially by both. The renal proteoglycans biglycan and decorin were detectable in glomeruli, with a significant increase in renal biglycan content in diabetic mice on the high-cholesterol diet. Renal biglycan and renal apolipoprotein B were colocalized, and regression analyses showed a significant relation between renal biglycan and renal apolipoprotein B content. The increased renal biglycan content in diabetic nephropathy probably contributes to renal lipid accumulation and the development of diabetic nephropathy.
Collapse
Affiliation(s)
- Joel Thompson
- Department of Veterans Affairs, Lexington, Kentucky, USA
| | | | | | | | | | | | | |
Collapse
|
10
|
Bhalodia Y, Sheth N, Vaghasiya J, Jivani N. Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury. Ren Fail 2010; 32:1088-94. [DOI: 10.3109/0886022x.2010.504911] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Elbarbry F, Ragheb A, Attia A, Chibbar R, Marfleet T, Shoker A. Cyclosporine-induced changes in drug metabolizing enzymes in hyperlipemic rabbit kidneys could explain its toxicity. Xenobiotica 2010; 40:772-81. [DOI: 10.3109/00498254.2010.517276] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
12
|
Taneja D, Thompson J, Wilson P, Brandewie K, Schaefer L, Mitchell B, Tannock LR. Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice. J Lipid Res 2010; 51:1464-70. [PMID: 20110440 DOI: 10.1194/jlr.m002972] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Hyperlipidemia is a risk factor for development and progression of diabetic nephropathy. However, it is not known if reduction of hyperlipidemia is protective against progression of disease. The goal of this study was to determine if reduction of hypercholesterolemia could limit progression of diabetic nephropathy. Diabetic and nondiabetic LDL receptor deficient (LDLR(-/-)) mice were fed diets containing either no cholesterol (0%) or high cholesterol (0.12%) for 36 weeks. One group each of diabetic and nondiabetic mice were fed the high-cholesterol diet for 26 weeks then changed to the 0% cholesterol diet for the last 10 weeks. Consumption of the high-cholesterol diet exacerbated the development of diabetic nephropathy with elevations in urine albumin excretion, glomerular and renal hypertrophy, and mesangial matrix expansion. Increased glomerular lipid and apolipoprotein B accumulation was found in diabetic mice that consumed the 0.12% cholesterol diet compared with other groups. However, diabetic mice that changed from the high-cholesterol diet to the 0% cholesterol diet for the last 10 weeks had lower urine albumin excretion and mesangial matrix expansion compared with mice that consumed the 0.12% cholesterol diet throughout. This suggests that hyperlipidemia causes continuous renal injury, and that lowering cholesterol levels by dietary means can improve renal function in diabetic LDLR(-/-) mice.
Collapse
Affiliation(s)
- Deepa Taneja
- Department of Veterans Affairs, Lexington, KY, USA
| | | | | | | | | | | | | |
Collapse
|
13
|
Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, Busto P, Richards RJ, Liu CL, Cheung R, Utz PJ, Marshak-Rothstein A, Rifkin IR. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2010; 184:796-806. [PMID: 20007534 PMCID: PMC2858062 DOI: 10.4049/jimmunol.0901748] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Polymorphisms in the transcription factor IFN regulatory factor 5 (IRF5) are strongly associated in human genetic studies with an increased risk of developing the autoimmune disease systemic lupus erythematosus. However, the biological role of IRF5 in lupus pathogenesis has not previously been tested in an animal model. In this study, we show that IRF5 is absolutely required for disease development in the FcgammaRIIB(-/-)Yaa and FcgammaRIIB(-/-) lupus models. In contrast to IRF5-sufficient FcgammaRIIB(-/-)Yaa mice, IRF5-deficient FcgammaRIIB(-/-)Yaa mice do not develop lupus manifestations and have a phenotype comparable to wild-type mice. Strikingly, full expression of IRF5 is required for the development of autoimmunity, as IRF5 heterozygotes had dramatically reduced disease. One effect of IRF5 is to induce the production of the type I IFN, IFN-alpha, a cytokine implicated in lupus pathogenesis. To address the mechanism by which IRF5 promotes disease, we evaluated FcgammaRIIB(-/-)Yaa mice lacking the type I IFN receptor subunit 1. Unlike the IRF5-deficient and IRF5-heterozygous FcgammaRIIB(-/-)Yaa mice, type I IFN receptor subunit 1-deficient FcgammaRIIB(-/-)Yaa mice maintained a substantial level of residual disease. Furthermore, in FcgammaRIIB(-/-) mice lacking Yaa, IRF5-deficiency also markedly reduced disease manifestations, indicating that the beneficial effects of IRF5 deficiency in FcgammaRIIB(-/-)Yaa mice are not due only to inhibition of the enhanced TLR7 signaling associated with the Yaa mutation. Overall, we demonstrate that IRF5 plays an essential role in lupus pathogenesis in murine models and that this is mediated through pathways beyond that of type I IFN production.
Collapse
Affiliation(s)
- Christophe Richez
- Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Chauhan V, Vaid M. Dyslipidemia in chronic kidney disease: managing a high-risk combination. Postgrad Med 2010; 121:54-61. [PMID: 19940417 DOI: 10.3810/pgm.2009.11.2077] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Cardiovascular disease (CVD) is the single largest cause of mortality in patients with chronic kidney disease (CKD), with those patients having a 10-year CVD-related morbidity and mortality of > 20%. This has led to the inclusion of CKD as a CVD equivalent, and justifies the aggressive treatment of modifiable risk factors such as dyslipidemia. Primary care physicians (PCP) often manage patients with CKD in the early stages of the disease and have a pivotal role in affecting long-term outcomes in CKD patients related to cardiovascular and all-cause mortality. Therefore, treatment of dyslipidemia often becomes the responsibility of the PCP and comes with its own set of challenges because of CKD-related issues (eg, the dose adjustments required). Exacerbating this problem is the fact that current guidelines are lengthy and complex. This article discusses the current guidelines for treating dyslipidemia in patients with CKD. Few studies have examined the safety and efficacy of pharmacotherapy for treatment of dyslipidemia in the CKD population, and ongoing studies such as the Study of Heart and Renal Protection (SHARP) should help clarify the current treatment guidelines.
Collapse
Affiliation(s)
- Veeraish Chauhan
- Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
| | | |
Collapse
|
15
|
Bhalodia Y, Sheth N, Vaghasiya J, Jivani N. Hyperlipidemia Enhanced Oxidative Stress and Inflammatory Response Evoked by
Renal Ischemia/Reperfusion Injury. INT J PHARMACOL 2009. [DOI: 10.3923/ijp.2010.25.30] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
16
|
Muñoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, Blanco-Colio LM. Tumor Necrosis Factor–Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout Mice. Arterioscler Thromb Vasc Biol 2009; 29:2061-8. [DOI: 10.1161/atvbaha.109.194852] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Tumor necrosis factor–like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor superfamily of cytokines. TWEAK binds and activates the Fn14 receptor, and may regulate apoptosis, inflammation, and angiogenesis, in different pathological conditions. We have evaluated the effect of exogenous TWEAK administration as well as the role of endogenous TWEAK on proinflammatory cytokine expression and vascular and renal injury severity in hyperlipidemic ApoE-knockout mice.
Methods and Results—
ApoE
−/−
mice were fed with hyperlipidemic diet for 4 to 10 weeks, then randomized and treated with saline (controls), TWEAK (10 μg/kg/d), anti-TWEAK neutralizing mAb (1000 μg/kg/d), TWEAK plus anti-TWEAK antibody (10 μg TWEAK +1000 μg anti-TWEAK/kg/d), or nonspecific IgG (1000 μg/kg/d) daily for 9 days. In ApoE
−/−
mice, exogenous TWEAK administration in ApoE
−/−
mice induced activation of NF-κB, a key transcription factor implicated in the regulation of the inflammatory response, in vascular and renal lesions. Furthermore, TWEAK treatment increased chemokine expression (RANTES and MCP-1), as well as macrophage infiltration in atherosclerotic plaques and renal lesions. These effects were associated with exacerbation of vascular and renal damage. Conversely, treatment of ApoE
−/−
mice with an anti-TWEAK blocking mAb decreased NF-κB activation, proinflammatory cytokine expression, macrophage infiltration, and vascular and renal injury severity, indicating a pathological role for endogenous TWEAK. Finally, in murine vascular smooth muscle cells or tubular cells, either ox-LDL or TWEAK treatment increased expression and secretion of both RANTES and MCP-1. Furthermore, ox-LDL and TWEAK synergized for induction of MCP-1 and RANTES expression and secretion.
Conclusion—
Our results suggest that TWEAK exacerbates the inflammatory response associated with a high lipid–rich diet. TWEAK may be a novel therapeutic target to prevent vascular and renal damage associated with hyperlipidemia.
Collapse
Affiliation(s)
- Begoña Muñoz-García
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - Juan Antonio Moreno
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - Oscar López-Franco
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - Ana Belén Sanz
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - José Luis Martín-Ventura
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - Julia Blanco
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - Aniela Jakubowski
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - Linda C. Burkly
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - Alberto Ortiz
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - Jesús Egido
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| | - Luis Miguel Blanco-Colio
- From the Renal and Vascular Research Laboratory, Fundación Jiménez Díaz (B.M.-G., J.A.M., O.L.-F., A.B.S., J.L.M.-V., A.O., J.E., L.M.B.-C.), Universidad Autónoma, Madrid, Spain; Hospital Clínico (J.B.), Madrid, Spain; and Biogen Idec (A.J., L.C.B.), Cambridge, Mass
| |
Collapse
|
17
|
Hoffler U, Hobbie K, Wilson R, Bai R, Rahman A, Malarkey D, Travlos G, Ghanayem BI. Diet-induced obesity is associated with hyperleptinemia, hyperinsulinemia, hepatic steatosis, and glomerulopathy in C57Bl/6J mice. Endocrine 2009; 36:311-25. [PMID: 19669948 PMCID: PMC4219357 DOI: 10.1007/s12020-009-9224-9] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2009] [Revised: 04/23/2009] [Accepted: 07/03/2009] [Indexed: 01/03/2023]
Abstract
Obesity and obesity-related illnesses are global epidemics impacting the health of adults and children. The purpose of the present work is to evaluate a genetically intact obese mouse model that more accurately reflects the impact of aging on diet-induced obesity and type 2 diabetes in humans. Male C57Bl/6J mice consumed either a control diet or one in which 60% kcal were due to lard beginning at 5-6 weeks of age. Body weight and fat measurements were obtained and necropsy performed at 15, 20, 30, and 40 weeks of age. Serum chemistry, histopathology, gene expression of the liver, and renal and hepatic function were also evaluated. In concert with significant increases in percent body fat and weight, mice fed the high-fat versus control diet had significantly increased levels of serum cholesterol. At ages 20 and 30 weeks, serum glucose was significantly higher in obese versus controls, while serum insulin levels were >/=4-fold higher in obese mice at ages 30 and 40 weeks. The effect of age exacerbated the effects of consuming a high-fat diet. In addition to being hyperinsulinemic and leptin resistant, older obese mice exhibited elevated hepatic PAI-1 and downregulation of GLUT4, G6PC, IGFBP-1, and leptin receptor mRNA in the liver, steatosis with subsequent inflammation, glomerular mesangial proliferation, elevated serum ALT, AST, and BUN, and increased numbers of pancreatic islets.
Collapse
Affiliation(s)
- Undi Hoffler
- Laboratory of Pharmacology, National Institutes of Health, National Institute of Environmental Health Sciences, National Institutes of Health, RTP, NC
- To whom correspondence should be addressed Undi Hoffler Laboratory of Pharmacology National Institutes of Health National Institute of Environmental Health Sciences RTP, NC 27709 (919) 541-0427
| | | | - Ralph Wilson
- Cellular and Molecular Pathology Branch, National Institutes of Health, National Institute of Environmental Health Sciences, National Institutes of Health, RTP, NC
| | - Re Bai
- Laboratory of Pharmacology, National Institutes of Health, National Institute of Environmental Health Sciences, National Institutes of Health, RTP, NC
| | - Akef Rahman
- Laboratory of Pharmacology, National Institutes of Health, National Institute of Environmental Health Sciences, National Institutes of Health, RTP, NC
| | - David Malarkey
- Cellular and Molecular Pathology Branch, National Institutes of Health, National Institute of Environmental Health Sciences, National Institutes of Health, RTP, NC
| | - Greg Travlos
- Cellular and Molecular Pathology Branch, National Institutes of Health, National Institute of Environmental Health Sciences, National Institutes of Health, RTP, NC
| | - Burhan I Ghanayem
- Laboratory of Pharmacology, National Institutes of Health, National Institute of Environmental Health Sciences, National Institutes of Health, RTP, NC
| |
Collapse
|
18
|
Floege J, Eitner F, Alpers CE. A New Look at Platelet-Derived Growth Factor in Renal Disease. J Am Soc Nephrol 2007; 19:12-23. [DOI: 10.1681/asn.2007050532] [Citation(s) in RCA: 235] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
|
19
|
Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, Barbosa I, Dedio J, Maffrand JP, Le Fur G, O'Connor S, Herbert JM. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 2007; 72:1345-57. [PMID: 17882151 DOI: 10.1038/sj.ki.5002540] [Citation(s) in RCA: 101] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Obesity is a major risk factor in the development of chronic renal failure. Rimonabant, a cannabinoid CB1 receptor antagonist, improves body weight and metabolic disorders; however, its effect on mortality and chronic renal failure associated with obesity is unknown. Obese Zucker rats received either rimonabant or vehicle for 12 months and were compared to a pair-fed but untreated group of obese rats. Mortality in the obese rats was significantly reduced by rimonabant along with a sustained decrease in body weight, transient reduction in food intake, and an increase in plasma adiponectin. This was associated with significant reduction in plasma total cholesterol, low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, glucose, norepinephrine, plasminogen activator inhibitor 1, and preservation of pancreatic weight and beta-cell mass index. The cannabinoid antagonist attenuated the increase in proteinuria, urinary N-acetylglucosaminidase excretion, plasma creatinine, and urea nitrogen levels while improving creatinine clearance. Renal hypertrophy along with glomerular and tubulointerstitial lesions were reduced by rimonabant. Although the drug did not modify hemodynamics, it normalized the pressor response to angiotensin II. Our study suggests that in a rat model of chronic renal failure due to obesity, rimonabant preserves renal function and increases survival.
Collapse
MESH Headings
- Adiponectin/blood
- Animals
- Body Weight/drug effects
- Body Weight/physiology
- Disease Models, Animal
- Eating/drug effects
- Eating/physiology
- Kidney/drug effects
- Kidney/physiology
- Kidney Failure, Chronic/etiology
- Kidney Failure, Chronic/prevention & control
- Lipids/blood
- Male
- Obesity/complications
- Obesity/drug therapy
- Obesity/metabolism
- Piperidines/pharmacology
- Piperidines/therapeutic use
- Pyrazoles/pharmacology
- Pyrazoles/therapeutic use
- Rats
- Rats, Zucker
- Receptor, Cannabinoid, CB1/antagonists & inhibitors
- Receptor, Cannabinoid, CB1/drug effects
- Receptor, Cannabinoid, CB1/physiology
- Rimonabant
- Survival Analysis
Collapse
Affiliation(s)
- P Janiak
- Cardiovascular Therapeutic Department, Sanofi-Aventis Research & Development, Chilly-Mazarin, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Buga GM, Frank JS, Mottino GA, Hakhamian A, Narasimha A, Watson AD, Yekta B, Navab M, Reddy ST, Anantharamaiah GM, Fogelman AM. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J Lipid Res 2007; 49:192-205. [PMID: 17925450 DOI: 10.1194/jlr.m700433-jlr200] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LDL receptor-null (LDLR(-/-)) mice on a Western diet (WD) develop endothelial dysfunction and atherosclerosis, which are improved by the apolipoprotein A-I (apoA-I) mimetic peptide D-4F. Focusing on the kidney, LDLR(-/-)mice were fed a WD with D-4F or the inactive control peptide scrambled D-4F (ScD-4F) added to their drinking water. The control mice (ScD-4F) developed glomerular changes, increased immunostaining for MCP-1/CCL2 chemokine, increased macrophage CD68 and F4/80 antigens, and increased oxidized phospholipids recognized by the EO6 monoclonal antibody in both glomerular and tublo-interstitial areas. All of these parameters were significantly reduced by D-4F treatment, approaching levels found in wild-type C57BL/6J or LDLR(-/-) mice fed a chow diet. Sterol-regulatory element binding protein-1c (SREBP-1c) mRNA levels and triglyceride levels were elevated in the kidneys of the control mice (ScD-4F) fed the WD compared with C57BL/6J and LDLR(-/-) mice on chow (P < 0.001 and P < 0.001, respectively) and compared with D-4F-treated mice on the WD (P < 0.01). There was no significant difference in plasma lipids, lipoproteins, glucose, blood pressure, or renal apoB levels between D-4F- and ScD-4F-treated mice. We conclude that D-4F reduced renal oxidized phospholipids, resulting in lower expression of SREBP-1c, which, in turn, resulted in lower triglyceride content and reduced renal inflammation.
Collapse
Affiliation(s)
- Georgette M Buga
- Department of Medicine, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, CA 90095-1679, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Combined treatment with niacin and chromium caused a protective effect on the small-intestine tissue of hyperlipidemic rats. Med Chem Res 2007. [DOI: 10.1007/s00044-007-9030-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
22
|
Inceli MS, Bolkent S, Doger MM, Yanardag R. The Effects of Combined Treatment with Niacin and Chromium on the Renal Tissues of Hyperlipidemic Rats. Mol Cell Biochem 2006; 294:37-44. [PMID: 17124636 DOI: 10.1007/s11010-006-9211-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2006] [Accepted: 04/07/2006] [Indexed: 11/24/2022]
Abstract
In this study, 12 months old female Swiss albino rats were used. They were randomly divided into four groups. The animals of group I were fed with pellet chow. Group II were fed with pellet chow and treated with 250 microg/kg CrCl3 x 6H2O and 100 mg/kg niacin for 45 days. Group III were fed a lipogenic diet consisting of 2% cholesterol, 0.5% cholic acid and 2% sunflower oil added to the pellet chow, and given 3%alcoholic water for 60 days. Group IV were fed with the same lipogenic diet for 60 day sand treated by gavage technique to rats at a dose of 250 micro/kg CrCl3 x 6H2O and 100 mg/kg niacin for 45 days, 15 days after experimental animals were rendered hyperlipidemic. At the 60th day, renal tissue and blood samples were taken from the animals. The sections were examined under light and electron microscopy. The degenerative changes were much more in the hyperlipidemic rats than the control group. The changes in renal tissue were also observed in hyperlipidemic animals given niacin and chromium. In the hyperlipidemic rats, renal glutathione levels decreased and renal lipid peroxidation levels, and serum urea and creatinine levels were increased. But, renal glutathione levels increased and lipid peroxidation levels and serum urea and creatinine levels decreased in hyperlipidemic rats given niacin and chromium. The purpose of this study was to investigate whether a protective effect of a combination of niacin and chromium is present on the renal tissue of hyperlipidemic rats or not. In conclusion, we can say that niacin and chromium do not have a protective effect on the morphology of the renal tissue of hyperlipidemic rats, except a protective effect on their biochemical parameters.
Collapse
Affiliation(s)
- Meliha Sengezer Inceli
- Department of Biology, Faculty of Science, Istanbul University, 34118, Vezneciler, Istanbul, Turkey.
| | | | | | | |
Collapse
|